Ajanta Pharma Limited , a prominent player in the pharmaceutical sector, has witnessed continued share pledging activities by its promoters. The latest disclosures show significant new pledge creations by key promoter Aayush Agrawal, adding to the series of recent transactions by promoters.

Latest Pledge Creation by Aayush Agrawal Trust

In the most recent disclosure dated December 31, 2025, Aayush Agrawal Trust reported the creation of a pledge on equity shares under SEBI SAST Regulations 2011. The transaction details are:

This follows another substantial pledge creation earlier in December, demonstrating ongoing financing activities by the promoter group.

Previous December 2025 Transactions

Prior to the latest disclosure, Aayush Agrawal had reported a major pledge creation on December 26, 2025, involving 16,02,500 shares for bank guarantee and increased loan purposes. Earlier in December 2025, Aayush Agrawal had also reported simultaneous pledge creation and release activities on December 17, 2025, involving pledging 6,38,500 shares while releasing 4,50,000 shares with Bajaj Finance Ltd.

Earlier Aayush Agrawal Activities

In October 2025, Aayush Agrawal had pledged 6,45,000 shares for new loan and additional margin purposes, disclosed on October 1, 2025, with multiple financial institutions including Deutsche Investments India Pvt Ltd, HSBC InvestDirect Financial Services India Ltd, and Jio Finance Ltd.

Ravi Agrawal's Share Transactions

In a separate disclosure dated October 3, 2025, Ravi Agrawal, another promoter of Ajanta Pharma, reported both creation and release of pledges:

Significant transactions included pledge creation of 10,50,000 shares with Emerging India Credit Opportunities Fund for business financing, along with multiple smaller transactions with various financial institutions.

Promoter Pledging Activity Summary

The recent series of pledging activities by Ajanta Pharma promoters demonstrates active financial management strategies. With multiple pledge creations by Aayush Agrawal Trust, including the latest 1,27,660 shares and earlier 16,02,500 shares in December 2025, the promoters continue to utilize their shareholdings for various financing requirements. These transactions are part of routine corporate financing activities and reflect ongoing business requirements including bank guarantees and loan facilities.

Motilal Oswal has maintained its 'Buy' rating on Ajanta Pharma with a target price of ₹3,145, citing strategic initiatives across India, Asia, and Africa markets. The brokerage firm indicates confidence in the pharmaceutical company's growth prospects with the updated price target reflecting positive expectations.

Target Price and Rating Details

The brokerage's recommendation includes specific financial targets for the pharmaceutical company:

Strategic Market Focus

The brokerage firm highlights that Ajanta Pharma is implementing multiple strategic initiatives across its focus branded generics markets. The company's primary geographic focus areas include:

• India
• Asia
• Africa

These strategic initiatives are positioned to help the pharmaceutical company sustain robust industry outperformance, according to the analyst assessment.

Market Positioning

The maintained 'Buy' recommendation with the specified target price suggests that Motilal Oswal views Ajanta Pharma's current market positioning and strategic direction favorably within the branded generics pharmaceutical segment. The brokerage's positive outlook is supported by Ajanta Pharma's targeted approach in key markets and its potential for continued growth in the pharmaceutical industry.